GlassScriptPhysician profile
Barry M Schanzer
NPI 1053456509
$2,335.98
in general payments reported to CMS, 2019-2025
25 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $286 · 2021: $355 · 2022: $369 · 2023: $275 · 2024: $242 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.92 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $484.50 | 2019-2025 | Cequa |
| Allergan, INC. | $279.19 | 2019-2021 | |
| Alcon Vision LLC | $275.70 | 2019-2025 | Rocklatan, Clareon, Eysuvis |
| Biotissue Holdings INC. | $171.88 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $154.34 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| Harrow Eye, LLC | $143.34 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $136.40 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $85.27 | 2020-2025 | Acthar |
| Oyster Point Pharma, INC. | $79.51 | 2022-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $71.49 | 2021-2022 | |
| Shire North American Group INC | $60.95 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.98 | 2019-2021 | |
| Dompe US, INC. | $47.34 | 2024-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $43.52 | 2019-2020 | |
| Abbvie INC. | $43.10 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $39.14 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $33.16 | 2025 | Syfovre |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $17.18 | 2023 | Omni Surgical System |
| Mallinckrodt Enterprises LLC | $17.01 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $16.67 | 2024 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $15.30 | 2019 | |
| Ocular Therapeutix, INC. | $14.20 | 2023 | Dextenza |
| Eyepoint US, INC. | $14.15 | 2019 | |
| Astellas Pharma US INC | $13.26 | 2023 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Schanzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.